English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduDeclines in prostate-specific antigen (PSA) level after treatment with the next-generation androgen receptor inhibitor drug enzalutamide predict improved survival rates in men with non-metastatic castration-resistant prostate cancer (nmCRPC), reports The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.
Tag: enzalutamide
Study suggests commonly used prostate cancer treatment rewires engine of prostate tumors
A new study from the University of Michigan Rogel Cancer Center suggests androgen receptor inhibitors can fundamentally rewire and reshape how prostate tumors function, and in certain cases even make them more aggressive. These findings will be published in Nature Communications on Sept. 15.
Prostate cancer regulator plays role in COVID-19, providing a promising treatment lead
By taking a lesson from prostate cancer, researchers now have a promising lead on a treatment for COVID-19. They found that, just like in prostate cancer, TMPRSS2 is regulated by the androgen receptor in the lungs. And notably, blocking the androgen receptor led to lower expression of TMPRSS2, which led to decreased coronavirus infection in mice and cellular models.